rivastigmine has been researched along with memantine in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 49 (35.00) | 29.6817 |
| 2010's | 70 (50.00) | 24.3611 |
| 2020's | 21 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazureau, JP; Burgy, G; Carreaux, F; Cochet, C; Delhommel, F; Durieu, E; Elkins, JM; Filippakopoulos, P; Knapp, S; Lo, DC; Meijer, L; Oberholzer, AE; Pearl, LH; Schmid, RS; Soundararajan, M; Tahtouh, T | 1 |
| Adam, BL; Gao, J; Terry, AV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gavrilova, SI; Zharikov, GA | 1 |
| Kamei, H; Nabeshima, T; Noda, Y | 1 |
| Hartmann, S; Möbius, HJ | 1 |
| Adler, G; Berger, FM; Calabrese, P; Frölich, L; Gertz, HJ; Hampel, H; Haupt, M; Jendroska, K; Kohler, J; Mielke, R; Paulus, HJ; Pilartz, H; Riepe, MW; Zedlick, D | 1 |
| Bonelli, RM | 1 |
| Fuchsberger, T; Hampel, H; Möller, HJ | 1 |
| Alhainen, K | 1 |
| Prasher, VP | 1 |
| Feldman, H; Portet, F; Reynish, E; Vellas, B; Voisin, T | 1 |
| van Dyck, CH | 1 |
| Enz, A; Gentsch, C | 1 |
| Herrmann, N; Lanctôt, KL; Thompson, S | 1 |
| Arya, P; Butler, R; Warner, J | 2 |
| Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D | 1 |
| Mehalic, T; Noviasky, JA; Pacific, DM; Peltz, G; Shatla, A | 1 |
| Kmietowicz, Z | 1 |
| Aisen, PS | 1 |
| Schölzel-Dorenbos, CJ | 1 |
| O'Neill, MF | 1 |
| Lublin, HK; Olsen, CE; Poulsen, HD | 1 |
| Burns, A; Olde Rikkert, MG; Oude Voshaar, RC | 1 |
| Auriacombe, S; Becker, H; Bourdeix, I; Dantoine, T; Pere, JJ; Sarazin, M | 1 |
| Clegg, A; Green, C; Kirby, J; Loveman, E; Payne, E; Picot, J; Takeda, A | 1 |
| Butler, R; Warner, J; Wuntakal, B | 1 |
| Nourhashémi, F | 1 |
| Verhey, FR | 1 |
| Johannsen, P | 1 |
| Farlow, MR | 1 |
| Adler, G; Gunay, I; Ibach, B; Riepe, MW; Tracik, F; Weinkauf, B | 1 |
| Kavirajan, H; Schneider, LS | 1 |
| Green, C | 1 |
| Lang, CJ | 1 |
| Gorelick, PB; Nyenhuis, DL | 1 |
| Adelman, A; Campos-Outcalt, D; Cross, JT; Forciea, MA; Hopkins, R; Mehr, D; Owens, DK; Qaseem, A; Santaguida, P; Schellhase, K; Shekelle, P; Snow, V | 1 |
| Booker, L; Cowan, D; Ismaila, A; Levine, M; Oremus, M; Patterson, C; Raina, P; Santaguida, P | 1 |
| Downey, D | 1 |
| Liao, S; Morrison, LJ | 1 |
| Athalye, S; Lefèvre, G; Picard, F; Pommier, F; Sedek, G; Shua-Haim, J; Smith, J | 1 |
| Graham, L | 1 |
| Ruis, J | 1 |
| Feldman, HH; Hsiung, GY | 1 |
| Hasselbalch, SG; Kampmann, JP | 1 |
| Crutchfield, D | 1 |
| Smith, DA | 1 |
| Bhatnagar, V; Brannan, S; Koumaras, B; Meng, X; Olin, JT; Reyes, P | 1 |
| Dominguez, J; Gauthier, S; Homma, A; Ikeda, M; O'Connor, D; Suh, GH; Wimo, A; Yang, BM | 1 |
| Alfonso, V; González-Adalid, M; Jiménez Caballero, PE; Sevilla, C | 1 |
| Leifer, BP | 1 |
| Alva, G; Farlow, MR; Meng, X; Olin, JT | 1 |
| Heuser, I; Laisney, O; Repantis, D | 1 |
| Formiga, F; Fort, I; Regalado, P; Robles, MJ; Rodriguez, D | 1 |
| Mimica, N; Presecki, P | 1 |
| Borah, B; Sacco, P; Zarotsky, V | 1 |
| Criado-Alvarez, JJ; Romo Barrientos, C | 1 |
| Osborn, GG; Saunders, AV | 1 |
| Appelt, DM; Balin, BJ; Galluzzi, KE | 1 |
| Hüll, M; Voigt-Radloff, S | 1 |
| Bohlken, J; Selke, GW; van den Bussche, H | 1 |
| Berrut, G; Bourdeix, I; Carcaillon, L; Dartigues, JF; Gillette, S; Pere, JJ; Sellal, F | 1 |
| Choi, SH; Han, HJ; Kim, EJ; Lee, JH; Na, DL; Park, KW; Shim, YS | 1 |
| Barone, E; Butterfield, DA; Mancuso, C; Preziosi, P; Siciliano, R | 1 |
| Yanagisawa, K | 1 |
| Okochi, M; Takeda, M; Tanaka, T | 1 |
| Guo, D; Hao, Z; He, D; Wu, B; Zhou, H | 1 |
| Caraci, F; Drago, F; Fedotova, J; Leggio, GM; Salomone, S | 1 |
| Atri, A | 1 |
| Aisen, PS; Cummings, J; Schneider, LS | 1 |
| Ansermot, N; Dobrinas, M; Eap, CB; Noetzli, M | 1 |
| Anderson, R; Bond, M; Davis, S; Hoyle, M; Hyde, C; Jeffreys, M; Miners, A; Moxham, T; Peters, J; Rogers, G; Thokala, P; Wailoo, A | 1 |
| Nakamura, Y | 1 |
| Cho, SJ; Choi, MS; Choi, SH; Han, HJ; Heo, JH; Kim, BC; Kim, KK; Lee, JY; Na, HR; Park, HY; Park, KW; Ryu, SH; Shin, JH; Yi, HA; Yoon, SJ | 1 |
| Sagar, R; Sonali, N; Subbiah, V; Tripathi, M; Velpandian, T | 1 |
| Eap, CB; Noetzli, M | 1 |
| Adorni, F; Caltagirone, C; Di Santo, SG; Musicco, M; Prinelli, F | 1 |
| Johnell, K; Sonde, L | 1 |
| Hattori, H | 1 |
| Arizaga, RL; Demey, I; Rojas, G | 1 |
| Ashoor, HM; Berliner, S; Chen, MH; Hemmelgarn, B; Ho, JM; Ng, CH; Soobiah, C; Straus, SE; Tricco, AC | 1 |
| Schmutz, JL; Trechot, P | 1 |
| Cumbo, E; Ligori, LD | 1 |
| Dong, S; Gao, X; He, D; Wang, D; Zhang, Y; Zhou, H | 1 |
| Hartikainen, S; Koponen, M; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM | 1 |
| Castagna, A; Cotroneo, AM; De Palo, G; Fabbo, A; Forgione, L; Gareri, P; Giacummo, A; Lacava, R; Marino, S; Putignano, D; Putignano, S; Simone, M; Zurlo, A | 1 |
| Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Wang, C; Wang, HF; Yu, JT; Zhu, XC | 1 |
| Akaishi, T | 1 |
| Utsumi, K | 1 |
| Ahnaou, A; Drinkenburg, WH; Huysmans, H; Jacobs, T | 1 |
| Cho, SJ; Choi, SH; Han, HJ; Kim, JE; Kim, SG; Kwon, JC; Moon, SY; Park, JM; Park, KC; Park, KH; Park, KW; Seo, SW | 1 |
| Eichler, T; Hertel, J; Hoffmann, W; Kilimann, I; Michalowsky, B; Teipel, S; Thyrian, JR; Wucherer, D | 1 |
| Farlow, MR; Grossberg, GT; Meng, X; Velting, DM | 1 |
| Heinrich, S; Hertel, J; Hoffmann, W; Meyer, S; Michalowsky, B; Schaefer-Walkmann, S; Thyrian, JR; Wübbeler, M; Wucherer, D | 1 |
| Chou, YJ; Chow, LH; Hu, HY; Huang, N; Li, CP; Wang, PN; Wu, CY | 1 |
| Chamberlin, KW; Ehret, MJ | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Matsuzono, K; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T | 1 |
| Ransmayr, G | 1 |
| Aref, H; Bassil, N; diTommaso, S; Kandiah, N; Lee, JH; Pai, MC; Srinivasan, AV; Yuksel, O | 1 |
| Lewis, SJ; Szeto, JY | 1 |
| Cantrell, FL; Pchelnikova, JL; Thornton, SL | 1 |
| Choi, SH; Han, HJ; Kim, EJ; Lee, JH; Na, DL; Na, HR; Park, KW; Shim, YS; Yoon, SJ | 1 |
| Deardorff, WJ; Grossberg, GT | 1 |
| Fišar, Z; Hroudová, J; Singh, N | 1 |
| Hartikainen, S; Lampela, P; Lavikainen, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM | 1 |
| Fujioka, S; Futagami, K; Kamimura, H; Ouma, S; Shibaguchi, H; Terasawa, M; Tsuboi, Y; Yasutaka, Y | 1 |
| Abe, K; Fukui, Y; Hishikawa, N; Ichinose, J; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T | 1 |
| Goebert, D; Guilloux, A; Higa, J; Lu, BY; Schultz, BR; Takeshita, J; Takeshita, S | 1 |
| Avila, A; Lawler, E | 1 |
| Bellman, S | 1 |
| Chang, SY; Dong, L; Feng, M; Guo, X; Hügel, H; Hyde, AJ; Lu, C; May, BH; Xue, CC; Zhang, AL | 1 |
| Hang, L; Jia, R; Li, J; Liang, J; Wang, Y; Wu, R; Xu, Y; Zhang, H | 1 |
| Buckley, N; Le Couteur, DG; Litchfield, M; McLachlan, AJ; Narayan, SW; Pearson, SA; Zoega, H | 1 |
| Bernal-Cobo, R; Calvo-Torres, LF; Gaviria-Mendoza, A; Machado-Alba, JE; Trujillo-Quintero, PM | 1 |
| Jacob, L; Kosik, J; Kostev, K; Kurylo, P | 1 |
| Alcaro, S; Borges, F; Chavarria, D; Gaspar, A; Mesiti, F | 1 |
| Sharma, P; Shrivastava, SK; Tripathi, MK | 1 |
| Honjo, Y; Ide, K; Takechi, H | 1 |
| Barthold, D; Drabo, EF; Ferido, P; Gray, SL; Joyce, G; Marcum, ZA; Zissimopoulos, J | 1 |
| Bülbül, EÖ; Karantas, ID; Mutlu, G; Okur, ME; Okur, NÜ; Siafaka, PI | 1 |
| Han, E; Kalisch Ellett, L; Lee, HJ; Lee, J; Roughead, EE | 1 |
| Castagna, A; Fabbo, A; Lacava, R; Manzo, C; Ruberto, C; Ruotolo, G | 1 |
| Halminen, O; Hörhammer, I; Linna, M; Mehtälä, J; Mikkola, T; Vesikansa, A; Virta, LJ; Ylisaukko-Oja, T | 1 |
| Harrington, CR; Klein, J; Kondak, C; Riedel, G; Wischik, CM | 1 |
| Cui, Y; Ren, G; Shi, X; Xu, Z | 1 |
| Lee, JH | 1 |
| Mehranfar, F; Saeedi, M | 1 |
| Bak, SH; Byeon, GH; Byun, J; Choi, HS; Chun, IK; Heo, J; Hong, Y; Jang, JW; Jeong, CW; Kasani, PH; Kim, JA; Kim, JH; Kim, JK; Kim, KL; Kim, S; Kim, WJ; Kim, Y; Kwon, SO; Lee, DY; Lee, EJ; Lee, K; Lee, SA; Moon, KW; Nam, SJ; Park, JI; Park, SW; Park, YJ; Rhee, HY | 1 |
| Ashoor, HM; Clarke, M; Hemmelgarn, BR; Holroyd-Leduc, J; Mavridis, D; Rios, P; Seitidis, G; Stewart, L; Straus, SE; Tricco, AC; Tudur-Smith, C; Veroniki, AA | 1 |
| Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA | 1 |
| Andrzejewski, K; Conde, SV; Jampolska, M; Kaczyńska, K; Mojzych, I | 1 |
| Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sadigh-Eteghad, S | 1 |
| Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T | 1 |
| Ando, A; Enomoto, H; Kose, E; Tate, N; Yamamoto, T; Yasuno, N | 1 |
| Yamada, M | 1 |
| Baddeley, TC; Harrington, CR; Klein, J; Kondak, C; Leith, M; Riedel, G; Santos, RX; Wischik, CM | 1 |
| Boada, M; Carnero-Pardo, C; Fortea, J; García-Ribas, G; Martínez-Lage, P; Olazarán, J; Sánchez-Juan, P; Viñuela, F | 1 |
64 review(s) available for rivastigmine and memantine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Estrogens; Ginkgo biloba; Humans; Indans; Memantine; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuronal Plasticity; Neuroprotective Agents; Neurotransmitter Agents; Nicergoline; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Piracetam; Pyrithioxin; Rivastigmine; Selegiline; Tacrine; Time Factors | 2001 |
[Anti-dementia drugs for Alzheimer disease in present and future].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; tau Proteins | 2002 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dementia; Dementia, Vascular; Donepezil; Dopamine Agents; Female; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Meta-Analysis as Topic; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Plant Preparations; Prospective Studies; Rivastigmine; Tacrine; Time Factors | 2003 |
[Mechanisms of action of Alzheimer medications].
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Rivastigmine | 2003 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2004 |
What are the treatment options for patients with severe Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2004 |
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseases; Cholinesterase Inhibitors; Clinical Trials as Topic; Comorbidity; Donepezil; Double-Blind Method; Drug Evaluation; Drug Interactions; Female; Galantamine; Gastrointestinal Diseases; Humans; Indans; Institutionalization; Longitudinal Studies; Male; Memantine; Meta-Analysis as Topic; Mice; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Single-Blind Method; Sleep Wake Disorders; Treatment Outcome | 2004 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
Dementia.
Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine | 2004 |
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Management; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Glutamic Acid; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2005 |
[Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Galantamine; Humans; Memantine; Netherlands; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2005 |
Drug therapy of dementia in elderly patients. A review.
Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2005 |
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Evidence-Based Medicine; Female; Galantamine; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome; United Kingdom | 2006 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Selegiline; Tacrine | 2005 |
[Pharmacotherapy for Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Topics: Cholinesterase Inhibitors; Dementia, Vascular; Diagnosis, Differential; Donepezil; Dopamine Agents; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Stroke | 2006 |
Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Topics: Cholinesterase Inhibitors; Databases, Bibliographic; Dementia, Vascular; Donepezil; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Odds Ratio; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors; Treatment Outcome | 2007 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine | 2007 |
[Are anti-dementia drugs worthwhile?].
Topics: Activities of Daily Living; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Drug Therapy, Combination; Economics, Medical; Excitatory Amino Acid Antagonists; Galantamine; Germany; Health Policy; Humans; Indans; Memantine; Meta-Analysis as Topic; Neuroprotective Agents; Nootropic Agents; Parasympathomimetics; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors | 2007 |
Diagnosis and management of vascular cognitive impairment.
Topics: Central Nervous System Agents; Clinical Trials as Topic; Cognition Disorders; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine | 2007 |
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
Pharmacologic management of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; N-Methylaspartate; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2008 |
Pharmacological treatment in moderate-to-severe Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine; Selegiline; Severity of Illness Index; Vitamin E | 2008 |
Discontinuing Alzheimer's disease drug therapy: why, when, and how.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Approval; Drug Monitoring; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nursing Homes; Patient Selection; Phenylcarbamates; Piperidines; Prevalence; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Failure; United States; Withholding Treatment | 2008 |
Treatment of Alzheimer's disease in the long-term-care setting.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Humans; Indans; Long-Term Care; Memantine; Phenylcarbamates; Piperidines; Rivastigmine | 2009 |
Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.
Topics: Cholinesterase Inhibitors; Cognition; Donepezil; Emotions; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Motivation; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2010 |
Current treatments for patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory Amino Acid Antagonists; Galantamine; Health Status; Humans; Memantine; Neuroprotective Agents; Parasympathomimetics; Phenylcarbamates; Psychomotor Agitation; Psychotherapy; Psychotic Disorders; Rivastigmine; Time Factors; United States; United States Food and Drug Administration | 2010 |
Modern care for patients with Alzheimer disease: rationale for early intervention.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory Amino Acid Antagonists; Humans; Immunosuppressive Agents; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Psychological Tests; Rivastigmine; Severity of Illness Index; Tacrolimus | 2010 |
[Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Caregivers; Donepezil; Galantamine; Geriatric Assessment; Ginkgo biloba; Humans; Indans; Institutionalization; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine | 2011 |
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Memantine; Neurons; Oxidative Stress; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Rivastigmine | 2011 |
[Newly approved drugs for Alzheimer disease: effectiveness and limitation].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2011 |
New drugs for Alzheimer's disease in Japan.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Japan; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2011 |
Pharmacologic treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Middle Aged; Multiple Sclerosis; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2011 |
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Topics: Alzheimer Disease; Clinical Trials as Topic; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Plaque, Amyloid; Rivastigmine; tau Proteins | 2012 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2011 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Donepezil; Drug Approval; Galantamine; Ginkgo biloba; Half-Life; History, 20th Century; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Psychotropic Drugs; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Sesquiterpenes; Vitamin B Complex; Vitamin E | 2012 |
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine; Technology Assessment, Biomedical | 2012 |
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Pharmacogenetics; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2013 |
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Disability Evaluation; Disease Progression; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2013 |
[Effectiveness and limitation of newly approved drugs for Alzheimer's disease].
Topics: Alzheimer Disease; Clinical Trials as Topic; Galantamine; Humans; Japan; Memantine; Phenylcarbamates; Quality of Life; Rivastigmine | 2013 |
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2013 |
Drugs for cognitive loss and dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2013 |
Pharmacological treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Middle Aged; Multiple Sclerosis; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2013 |
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2014 |
[Memory-enhancing drugs].
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP Response Element-Binding Protein; Donepezil; Drug Discovery; Extracellular Signal-Regulated MAP Kinases; Galantamine; Hippocampus; Humans; Indans; Long-Term Potentiation; Memantine; Memory; Memory Disorders; Molecular Targeted Therapy; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Synaptic Transmission | 2014 |
[Progress of dementia medicine: Special reference to Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Magnetic Resonance Imaging; Memantine; Neurofibrillary Tangles; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Tomography, Emission-Computed, Single-Photon | 2014 |
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Piperidines; Rivastigmine; Treatment Outcome | 2015 |
Cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Memantine; Muscle Rigidity; Parkinson Disease; Risk Factors; Rivastigmine | 2015 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Exercise Therapy; Galantamine; Humans; Indans; Memantine; Parkinson Disease; Piperidines; Rivastigmine; Sleep Wake Disorders; Treatment Outcome | 2016 |
Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Memantine; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Transdermal Patch | 2016 |
Alzheimer Disease: Monotherapy vs. Combination Therapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Piperidines; Rivastigmine | 2017 |
Pharmacological treatment for memory disorder in multiple sclerosis.
Topics: Adult; Donepezil; Ginkgo biloba; Humans; Indans; Memantine; Memory Disorders; Multiple Sclerosis; Neuroprotective Agents; Nootropic Agents; Phytotherapy; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2017 |
Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes.
Topics: Alzheimer Disease; Asia, Eastern; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Medicine, Traditional; Memantine; Nootropic Agents; Piperidines; Plant Extracts; Rivastigmine | 2018 |
Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.
Topics: Alzheimer Disease; Antiparkinson Agents; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Rivastigmine | 2018 |
The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chemistry Techniques, Synthetic; Donepezil; Dopamine Agents; Drug Design; Drug Discovery; Humans; Indans; Memantine; Molecular Targeted Therapy; Neuroprotective Agents; Nootropic Agents; Rivastigmine; Tacrine | 2019 |
Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Delivery Systems; Humans; Memantine; Rivastigmine | 2020 |
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Network Meta-Analysis; Nootropic Agents; Randomized Controlled Trials as Topic; Rivastigmine | 2022 |
Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal, Humanized; Donepezil; Indans; Memantine; Patents as Topic; Piperidines; Rivastigmine | 2022 |
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Topics: Adult; Alzheimer Disease; Donepezil; Galantamine; Humans; Memantine; Network Meta-Analysis; Nootropic Agents; Rivastigmine | 2022 |
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Memantine; Parkinson Disease; Quality of Life; Rivastigmine | 2021 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Glycogen Synthase Kinase 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indans; Lithium; Melatonin; Memantine; Neurodegenerative Diseases; Rivastigmine; Systematic Reviews as Topic | 2022 |
[Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Memantine; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2023 |
11 trial(s) available for rivastigmine and memantine
| Article | Year |
|---|---|
Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Topics: Aged; Alzheimer Disease; Antiparasitic Agents; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Memantine; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Treatment Outcome | 2006 |
Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Memory; Phenylcarbamates; Pilot Projects; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2007 |
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indans; Male; Memantine; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Male; Memantine; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2011 |
Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Genotype; Humans; Male; Memantine; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Transdermal Patch | 2012 |
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Longitudinal Studies; Male; Memantine; Mental Disorders; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine | 2014 |
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Comorbidity; Donepezil; Female; Galantamine; Humans; Indans; Italy; Male; Memantine; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Retrospective Studies; Rivastigmine; Time Factors; Treatment Outcome | 2014 |
Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Butyrylcholinesterase; Female; Genetic Testing; Genotype; Humans; Male; Memantine; Middle Aged; Neuroprotective Agents; Odds Ratio; Rivastigmine; Transdermal Patch | 2015 |
Antidementia drug treatment in people screened positive for dementia in primary care.
Topics: Aged; Aged, 80 and over; Dementia; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Mental Status Schedule; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Primary Health Care; Rivastigmine | 2015 |
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Memantine; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Quality of Life; Rivastigmine; Transdermal Patch; Treatment Outcome | 2015 |
Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Follow-Up Studies; Humans; Male; Memantine; Multivariate Analysis; Prospective Studies; Psychomotor Agitation; Republic of Korea; Risk Assessment; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
65 other study(ies) available for rivastigmine and memantine
| Article | Year |
|---|---|
Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Topics: Alkaloids; Amyloid beta-Protein Precursor; Animals; Brain; Cell Death; Cell Line; Chromatography, Affinity; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Dioxoles; Dyrk Kinases; Glutamic Acid; Humans; Imidazoles; In Vitro Techniques; Mice; Models, Molecular; Molecular Structure; Neuroprotective Agents; Porifera; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship | 2012 |
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cotinine; Humans; Neurons; Neuroprotective Agents; Nicotine; Peptide Fragments; Rats; Receptors, N-Methyl-D-Aspartate | 2014 |
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Middle Aged; Phenylcarbamates; Piperidines; Product Surveillance, Postmarketing; Rivastigmine; Surveys and Questionnaires; Tacrine; Treatment Outcome | 2003 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihydroergotoxine; Donepezil; Family Practice; Female; Follow-Up Studies; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nimodipine; Nootropic Agents; Phenylcarbamates; Piperidines; Piracetam; Psychiatric Status Rating Scales; Risk Factors; Rivastigmine; Time Factors; Vasodilator Agents | 2002 |
Editorial comment--How to treat vascular dementia?
Topics: Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2003 |
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2004 |
Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Brain; Brain Chemistry; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Interactions; Excitatory Amino Acid Antagonists; In Vitro Techniques; Inhibitory Concentration 50; Male; Mass Spectrometry; Memantine; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Time Factors | 2004 |
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Male; Memantine; Mice; Mice, Mutant Strains; Phenylcarbamates; Piperidines; Rivastigmine; Sensitivity and Specificity | 2005 |
Seizures associated with memantine use.
Topics: Aged; Benzodiazepines; Dopamine Agents; Drug Synergism; Female; Humans; Memantine; Neuroprotective Agents; Olanzapine; Phenylcarbamates; Rivastigmine; Seizures; Sertraline | 2005 |
NICE proposes to withdraw Alzheimer's drugs from NHS.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Drug Costs; England; Formularies as Topic; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; State Medicine; Wales | 2005 |
UK government guidance on Alzheimer's drugs postponed.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Excitatory Amino Acid Antagonists; Federal Government; Galantamine; Government Regulation; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; United Kingdom | 2005 |
Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; European Union; Galantamine; Humans; Indans; Memantine; Neurotransmitter Agents; Phenylcarbamates; Piperidines; Reimbursement Mechanisms; Rivastigmine | 2006 |
[Advances in Alzheimer's disease treatment].
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine | 2006 |
Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Quality of Life; Rivastigmine; Tacrine | 2008 |
Dementia medications in palliative care #174.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Palliative Care; Phenylcarbamates; Piperidines; Prognosis; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2008 |
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Benzylamines; Cholinesterase Inhibitors; Cross-Over Studies; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Middle Aged; Phenethylamines; Phenols; Phenylcarbamates; Rivastigmine | 2008 |
AAFP and ACP release guideline on dementia treatment.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Guidelines as Topic; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2008 |
[Alzheimer type dementia].
Topics: Alzheimer Disease; Apolipoprotein E4; Diagnosis, Differential; Disease Progression; Donepezil; Humans; Indans; Memantine; Neuroprotective Agents; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine | 2008 |
[Treatment of degenerative dementia disorders--who should be treated?].
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Dopamine Agents; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lewy Body Disease; Memantine; Middle Aged; Neuroprotective Agents; Parkinson Disease; Patient Selection; Phenylcarbamates; Rivastigmine | 2009 |
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Blood Pressure; Capsules; Cholinesterase Inhibitors; Cognition; Dizziness; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans; Incidence; Male; Memantine; Middle Aged; Nausea; Phenylcarbamates; Pilot Projects; Prospective Studies; Rivastigmine; Vomiting | 2010 |
International price comparisons of Alzheimer's drugs: a way to close the affordability gap.
Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Developing Countries; Donepezil; Drug Costs; Economics; Galantamine; Humans; Income; Indans; India; Memantine; Mexico; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; United States | 2009 |
Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cross-Sectional Studies; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Patient Compliance; Patient Satisfaction; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Rivastigmine; Socioeconomic Factors; Spain; Surveys and Questionnaires | 2009 |
Alzheimer's disease: Seeing the signs early.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Primary Health Care; Psychometrics; Rivastigmine; Time Factors | 2009 |
Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Drug Utilization; Female; Galantamine; Geriatric Assessment; Humans; Indans; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Psychotropic Drugs; Rivastigmine; Socioeconomic Factors | 2010 |
How do we treat people with dementia in Croatia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Croatia; Cross-Cultural Comparison; Cross-Sectional Studies; Donepezil; Drug Approval; Drug Costs; Humans; Indans; Memantine; National Health Programs; Nootropic Agents; Phenylcarbamates; Piperidines; Reimbursement Mechanisms; Rivastigmine | 2010 |
Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dopamine Agents; Female; Galantamine; Humans; Indans; Insurance Claim Review; Logistic Models; Male; Medication Adherence; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Predictive Value of Tests; Retrospective Studies; Rivastigmine; Treatment Outcome | 2010 |
[Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Observer Variation; Phenylcarbamates; Piperidines; Plant Extracts; Rivastigmine; Spain; Substance-Related Disorders | 2010 |
[Prescription differences of dementia drugs in urban and rural areas in Germany].
Topics: Aged; Alzheimer Disease; Ambulatory Care; Donepezil; Galantamine; General Practice; Germany; Humans; Indans; Medically Underserved Area; Memantine; Neuropsychiatry; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Patterns, Physicians'; Rivastigmine; Rural Population; Urban Population; Workforce | 2011 |
Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Disease Progression; Educational Status; Female; Geriatric Assessment; Humans; Institutionalization; Logistic Models; Male; Memantine; Middle Aged; Observation; Phenylcarbamates; Qualitative Research; Risk Factors; Rivastigmine; Surveys and Questionnaires | 2011 |
Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Donepezil; Drug Stability; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenethylamines; Phenols; Phenylcarbamates; Piperidines; Plasma; Reference Standards; Reproducibility of Results; Rivastigmine; Tandem Mass Spectrometry | 2012 |
[New anti-AD drugs--their possibilities and issues].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; N-Methylaspartate; Phenylcarbamates; Rivastigmine | 2012 |
Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Gene Frequency; Glucuronosyltransferase; Humans; Male; Memantine; Middle Aged; Pharmacogenetics; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2013 |
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galantamine; Humans; Indans; Male; Medical Records; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Health Care; Retrospective Studies; Rivastigmine; Sweden; Treatment Outcome | 2013 |
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Child; Child, Preschool; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Dementia, Vascular; Donepezil; Drug Prescriptions; Female; Galantamine; Humans; Indans; Infant; Male; Memantine; Middle Aged; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Young Adult | 2013 |
[Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
Topics: Adrenal Cortex Hormones; Aged; Alanine; Alzheimer Disease; Amyloid Precursor Protein Secretases; Azepines; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Humans; Keratinocytes; Memantine; Models, Biological; Nootropic Agents; Phenylcarbamates; Psoriasis; Receptors, Notch; Rivastigmine; Signal Transduction | 2013 |
Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Donepezil; Drug Monitoring; Drug Prescriptions; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Finland; Follow-Up Studies; Galantamine; Guideline Adherence; Humans; Indans; Male; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Proportional Hazards Models; Registries; Rivastigmine | 2014 |
Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential.
Topics: Animals; Cerebral Cortex; Cognition; Donepezil; Drug Evaluation, Preclinical; Electrodes, Implanted; Electroencephalography; Galantamine; Gamma Rhythm; Indans; Male; Memantine; Motor Activity; Muscarinic Antagonists; Neural Pathways; Nootropic Agents; Phenylcarbamates; Piperidines; Principal Component Analysis; Rats, Sprague-Dawley; Rivastigmine; Scopolamine; Signal Processing, Computer-Assisted; Tacrine; Theta Rhythm | 2014 |
Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use.
Topics: Aged; Aged, 80 and over; Caregivers; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Female; Galantamine; Germany; Humans; Indans; Interviews as Topic; Logistic Models; Male; Memantine; Neuroprotective Agents; Nootropic Agents; Piperidines; Rivastigmine | 2015 |
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan.
Topics: Cohort Studies; Dementia; Dihydroergocristine; Dihydroergotamine; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Piperidines; Piracetam; Proportional Hazards Models; Retrospective Studies; Rivastigmine; Taiwan; Time Factors | 2015 |
Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Japan; Male; Memantine; Piperidines; Retrospective Studies; Rivastigmine; Treatment Outcome | 2015 |
Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Asia; Attitude of Health Personnel; Caregivers; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Memantine; Middle East; Patient Preference; Physicians; Piperidines; Prospective Studies; Rivastigmine | 2015 |
Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System.
Topics: Child; Child, Preschool; Dementia; Donepezil; Female; Galantamine; Humans; Indans; Infant; Male; Memantine; Nootropic Agents; Piperidines; Poison Control Centers; Retrospective Studies; Rivastigmine | 2016 |
In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Indans; Memantine; Mitochondria; Monoamine Oxidase; Nootropic Agents; Oxygen Consumption; Piperidines; Rivastigmine; Swine | 2017 |
Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Finland; Galantamine; Hospitalization; Humans; Indans; Male; Memantine; Middle Aged; Piperidines; Pneumonia; Risk; Rivastigmine | 2017 |
Influence of Memantine on Continuous Treatment with Rivastigmine Patches-Retrospective Study Using the Logistic Regression Analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Memantine; Middle Aged; Patient Compliance; Retrospective Studies; Rivastigmine; Transdermal Patch | 2017 |
Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Male; Memantine; Nootropic Agents; Rivastigmine; Severity of Illness Index; Treatment Outcome; White Matter | 2017 |
Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders.
Topics: Aged; Aged, 80 and over; Asian People; Cholinergic Antagonists; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Galantamine; Hawaii; Hospitals, Urban; Humans; Indans; Male; Memantine; Native Hawaiian or Other Pacific Islander; Pacific Islands; Piperidines; Retrospective Studies; Rivastigmine | 2017 |
Anticholinergic medicines use among older adults before and after initiating dementia medicines.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Australia; Cholinergic Antagonists; Cholinesterase Inhibitors; Dementia; Deprescriptions; Donepezil; Drug Prescriptions; Female; Humans; Male; Memantine; Middle Aged; Retrospective Studies; Risperidone; Rivastigmine | 2019 |
[Patterns of antidemential drug use in a group of patients from Colombia].
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colombia; Cross-Sectional Studies; Dementia; Donepezil; Drug Utilization; Female; Galantamine; Humans; Male; Memantine; Middle Aged; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2019 |
One-Year Persistence with Donepezil, Memantine, and Rivastigmine in More than 66,000 Elderly Patients Followed in Poland.
Topics: Aged; Alzheimer Disease; Donepezil; Drug Utilization Review; Female; Humans; Male; Medication Adherence; Memantine; Middle Aged; Neuroprotective Agents; Outcome Assessment, Health Care; Poland; Practice Patterns, Physicians'; Rivastigmine | 2019 |
Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Development; Galantamine; Humans; Memantine; Rivastigmine | 2020 |
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Donepezil; Female; Galantamine; Humans; Japan; Male; Memantine; Mental Status and Dementia Tests; Retrospective Studies; Rivastigmine | 2020 |
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Female; Galantamine; Healthcare Disparities; Humans; Male; Medicare; Memantine; Nootropic Agents; Patient Acceptance of Health Care; Rivastigmine; Treatment Outcome; United States | 2020 |
Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage.
Topics: Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Galantamine; Global Health; Humans; Memantine; Product Surveillance, Postmarketing; Republic of Korea; Rivastigmine; Universal Health Care | 2021 |
The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cognition; Comorbidity; Cytidine Diphosphate Choline; Female; Humans; Italy; Male; Memantine; Retrospective Studies; Rivastigmine | 2021 |
Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Female; Finland; Galantamine; Humans; Male; Memantine; Nootropic Agents; Nursing Homes; Retrospective Studies; Rivastigmine; Time-to-Treatment | 2021 |
Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Cholinesterase Inhibitors; Dopamine Agents; Drug Interactions; Female; Hippocampus; Memantine; Methylene Blue; Mice; Mice, Transgenic; Rivastigmine; Signal Transduction | 2022 |
The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine | 2022 |
Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine | 2022 |
Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer's Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Disease Models, Animal; Humans; Hypercapnia; Hypoxia; Memantine; Mice; Mice, Transgenic; Quality of Life; Respiration; Rivastigmine | 2022 |
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine; Deglutition Disorders; Donepezil; Galantamine; Humans; Memantine; Penicillamine; Risk Management; Rivastigmine; United States; United States Food and Drug Administration | 2022 |
Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database.
Topics: Acetylcholinesterase; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effects and Adverse Reactions; Galantamine; Humans; Indans; Memantine; Piperidines; Rivastigmine | 2023 |
Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Memantine; Mice; Mice, Transgenic; Mitochondria; Rivastigmine; tau Proteins | 2023 |
Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; COVID-19; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Pandemics; Phenylcarbamates; Piperidines; Prevalence; Retrospective Studies; Rivastigmine | 2023 |